Exalenz Plunges Most in Five Months as Investment Talks End

April 30 (Bloomberg) -- Exalenz Bioscience Ltd. plunged the most in five months in Tel Aviv trading after the maker of breath-testing systems ended talks to receive an investment from a private fund.

Exalenz tumbled 12 percent, the biggest intraday slump since Nov. 29, to 0.3520 shekel as of 3:58 p.m. in Tel Aviv, trimming its market value to 47 million shekels ($13 million).

To contact the reporter on this story: David Wainer in Tel Aviv at dwainer3@bloomberg.net

To contact the editor responsible for this story: Claudia Maedler at cmaedler@bloomberg.net